Neuralink Achieves FDA Breakthrough Device Status for Blindsight Implant
Neuralink's Blindsight Implant Aims to Restore Vision
Neuralink, founded by Elon Musk in 2016, has made significant strides with its latest innovation, the Blindsight implant. This experimental device has recently received a breakthrough device designation from the U.S. Food and Drug Administration (FDA), aimed at restoring vision even for those who have lost both eyes and optic nerves.
FDA's Breakthrough Device Designation
The FDA's breakthrough device tag is granted to certain medical devices that provide treatment or diagnosis of life-threatening conditions and accelerates development and review. Neuralink's Blindsight implant is designed to process and transmit neural signals, possibly allowing users to see again.
Clinical Trials and Future Prospects
Details regarding the timeline for human trials have yet to be released. Meanwhile, Neuralink is also testing a separate implant aimed at assisting paralyzed patients to access digital devices through thought alone. This study includes several patients and is projected to take several years, marking a significant development in the field of neurotechnology.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.